Dizziness under Control: From Myths to Clinical Strategies | Ukrainian Medical Journal

Dizziness is a common symptom with significant clinical implications, often serving as a marker of cardiovascular and neurological disorders. Its prevalence reaches 30% among individuals over 65 years and is strongly associated with falls, reduced quality of life, anxiety, and depression. This article reviews prevalent misconceptions and highlights the need for a comprehensive diagnostic and therapeutic approach. Contemporary management considers dizziness an independent therapeutic target. Pharmacological treatment relies on agents with proven efficacy, such as cinnarizine and dimenhydrinate. Their fixed-dose combination exerts synergistic effects on both peripheral and central mechanisms, ensuring faster symptom control and reduced recurrence risk. Evidence from randomized trials and meta-analyses demonstrates the superiority of fixed combination of the cinnarizine (20 mg)/dimenhydrinate (40 mg) over monotherapy or betahistine.

References

1. vestibular.org/balance-awareness-week.
2. Dros J., Maarsingh O.R., Beem L. et al. (2011) Impact of dizziness on everyday life in older primary care patients: a cross-sectional study. Health Qual Life Outcomes, 9: 44. doi: 10.1186/1477-7525-9-44.
3. Kammerlind A.S., Peolsson A., Johansson M.M. (2022) Dizziness in older persons at high risk of future hospitalization: prevalence, differences between those with and without dizziness, and effect of a proactive primary care intervention. BMC Geriatr., 22(1): 315. doi: 10.1186/s12877-022-02910-1.
4. Müller R., Zangger P., Straumann D. et al. (2022) Dizziness and benign paroxysmal positional vertigo among retirement home residents: a cross-sectional descriptive and interventional study. BMC Geriatr., 22(1): 120. doi: 10.1186/s12877-022-02818-w.
5. What are the Most Common Causes of Dizziness. ent-md.com/news/what-are-the-most-common-causes-of-dizziness/.
6. Dizziness: Causes, Symptoms & Support Strategies. drjockers.com/dizziness/.
7. Krieger J., Frackowiak M., Berger M. et al. (2022) Falls at advanced age — The importance to search for benign paroxysmal positional vertigo (BPPV). Exp. Gerontol., 165: 111868. doi: 10.1016/j.exger.2022.111868.
8. Rogers T.S., Noel M.A., Garcia B. (2023) Dizziness: Evaluation and Management. Am. Fam. Physician., 107(5): 514–523. PMID: 37192077.
9. Cheng H.J., Sun Z.J., Lu F. et al. (2023) Functional status associated with postural dizziness, but not postural hypotension, in older adults: a community-based study. BMC Geriatr., 23(1): 383. doi: 10.1186/s12877-023-04100-z.
10. Sana V., Ghous M., Kashif M. et al. (2023) Effects of vestibular rehabilitation therapy versus virtual reality on balance, dizziness, and gait in patients with subacute stroke: A randomized controlled trial. Medicine (Baltimore), 102(24): e33203. doi: 10.1097/MD.0000000000033203.
11. Scholtz A.W., Ilgner J., Loader B. et al. (2016) Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin. Wochenschr., 128(9–10): 341–347. doi: 10.1007/s00508-015-0905-5.
12. Kirtane M., Bhandari A., Narang P. et al. (2019) Cinnarizine: A Contemporary Review. Indian J. Otolaryngol. Head Neck Surg., 71(Suppl. 2): 1060–1068. doi: 10.1007/s12070-017-1120-7.
13. Hahn A., Sejna I., Stefflova B. et al. (2008) A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study. Clin. Drug Investig., 28(2): 89–99. doi: 10.2165/00044011-200828020-00003.
14. Scholtz A.W., Waldfahrer F., Hampel R. et al. (2022) Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. Clin Drug Investig., 42(9): 705–720. doi: 10.1007/s40261-022-01184-0.